RCUSArcus Biosciences, Inc.

$2B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+248.8% YoY

Gross Profit

$33M100.0% margin

Operating Income

-$70M-212.1% margin

Net Income

-$65M-197.0% margin

EPS (Diluted)

$-0.84

QoQ Revenue Growth

+22.2%

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$82M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$695M

Stockholders' Equity

$699M

Cash & Equivalents

$218M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$9M	+248.8%
Gross Profit	$33M	$9M	+248.8%
Operating Income	-$70M	-$78M	+10.4%
Net Income	-$65M	-$78M	+16.6%

Revenue Segments

License and Development Services for All Gilead Programs

$24M71%

Gilead Access Rights

$8M25%

Taiho Access Rights

$2M5%

RCUS Q3 2022 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena